How GLP-1s work: Biology made therapeutics GLP-1 is an intestinal hormone released after meals
The type of control and study location were identified as sources of high heterogeneity following subgroup analysis
The first evidence for the presence of GSTs in bacteria was reported more 30 years ago by Takashi Shishido who showed the presence of GST activity in a strain of [71]
Search items included medication-related itemsGLP-1 receptor agonist, GLP-1RA, dual-agonist, and glucagon-like peptide-1 along with cardiovascular outcome-related items major adverse cardiovascular event, myocardial infarction, coronary artery disease, peripheral arterial disease, heart failure, hypertension, and atrial fibrillation. Studies were meticulously screened and included if they reported cardiovascular outcomes related to MACE, myocardial infarction (MI), CAD, PAD, HF, hypertension (HTN), or AF